Spotlight Growth
No Result
View All Result
Monday, March 20, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Checkmate Pharmaceuticals (NASDAQ: CMPI) Skyrockets 333% After Agreement to be Acquired by Regeneron (NASDAQ: REGN) for $250 Million

by admin
April 19, 2022
in Bio/Med/Pharma
0
Checkmate Pharmaceuticals NASDAQ CMPI Regeneron NASDAQ REGN Acquisition Spotlight Growth

Checkmate Pharmaceuticals NASDAQ CMPI Regeneron NASDAQ REGN Acquisition Spotlight Growth

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) is engaged as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to develop immunotherapies targeting cancer. Shares of the biotech company are skyrocketing 333% through early trading on Tuesday, April 19, 2022. Over the past three months, Checkmate Pharmaceuticals has seen average daily volume of 13,630 shares. However, volume of 1.75 million shares or dollar volume of around $18.25 million, has already exchanged hands through early trading.

Shares of Checkmate Pharmaceuticals are soaring after the company announced it had entered into a definitive agreement to be acquired by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Under the agreement, Regeneron will pay $10.50 per share of Checkmate common stock in an all-cash deal worth $250 million. If approved, the acquisition is estimated to close in mid-2022.

Regeneron looks to bolster its already-impressive portfolio of immuno-oncology drug candidates with Checkmate’s vidutolimod, which is currently being studied as a combination drug for melanoma, non-melanoma skin cancer, and head and neck cancer.

Vidutolimod is administered directly into the tumor, which is believed to induce, develop anti-tumor T-cells and trigger tumor regression. The treatment is designed for use as a monotherapy in patients whose tumors have progressed on PD-1 checkpoint inhibition.

“As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: acquisitionbiopharmaceuticalsbiotechbiotechnology stocksCheckmate Pharmaceuticalsclinical studiesclinical trialsCMPICMPI stockcommon stockday trading stockdow jones todayemerging growthFDAinvestinginvesting newsinvestmentmedicalMergermicrocap stocksNASDAQnasdaq stocknewsnews alertoncology stockspharmapharmaceuticalspublic companyRegeneronREGNREGN stocksalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstockstock marketstock market newsstockstradingtreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023
Why Investors Are Worried About Credit Suisse NYSE CS Spotlight Growth

Why Are Investors Worried About Credit Suisse (NYSE: CS)?

March 15, 2023
Zero Days Till Expiration 0 DTE Options Trading Spotlight Growth

Zero Days Till Expiration (0 DTE) Options Trading: A High-Risk Strategy for Experienced Investors

March 15, 2023
ThermoGenesis NASDAQ THMO cGMP Facility Sacramento CA Spotlight Growth

ThermoGenesis (NASDAQ: THMO) Prepares Launch of ReadyStart cGMP Suites for Cell & Gene Therapy Companies

March 15, 2023

Recent News

PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023
Why Investors Are Worried About Credit Suisse NYSE CS Spotlight Growth

Why Are Investors Worried About Credit Suisse (NYSE: CS)?

March 15, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested